Canadian Journal of Infectious Diseases and Medical Microbiology

Research Article

Analysis of the Influencing Factors of Immunological Nonresponders in Wuhan, China

Table 3

The CD4⁺ cell count increase of different influencers.


Influencers		CD4⁺ cell count increase

Gender	Male (N = 197)	93.0 (39.0, 133.0)	0.716
Gender	Female (N = 23)	89.0 (−7.0, 137.0)	0.716
BMI (kg/m²)^a	<18.5 (N = 43)	94.0 (26.0, 151.0)	0.151
	18.5–25.0 (N = 153)	96.0 (53.0, 133.5)
	≥25.0 (N = 17)	56.0 (16.0, 98.0)
	Missing (N = 7)	111.0 (−142.0, 166.0)
Age at follow-up (years)^b	<29 (N = 21)	96.0 (41.5, 128.5)	0.615
	29–39 (N = 40)	94.5 (25.3, 158.3)
	39–49 (N = 30)	93.5 (−1.0, 155.0)
	≥49 (N = 129)	92.0 (49.5, 130.0)
Duration from HIV diagnosis to HAART start (months)^b	<1 (N = 71)	107.0 (55.0, 148.0)	0.014
	1–3 (N = 101)	94.0 (51.0, 132.0)
	≥3 (N = 48)	65.0 (−48.5, 127.0)
Duration of HAART (months)^b	12–24 (N = 73)	97.0 (57.5, 128.5)	0.172
	24–48 (N = 72)	100.0 (44.5, 146.8)
	>48 (N = 75)	81.0 (12.0, 133.0)
Transmission route	Drug use (N = 3)	—	0.420
	Homosexual (N = 97)	86.0 (27.0, 134.5)
	Heterosexual (N = 113)	98.0 (55.0, 135.0)
	Missing (N = 7)	57.0 (−12.0, 123.0)
WHO clinical stage^a	I (N = 12)	53.0 (−59.0, 114.5)	0.078
	II (N = 63)	86.0 (25.0, 129.0)
	III (N = 93)	89.0 (42.0, 149.5)
	IV (N = 52)	108.5 (74.8, 133.0)
Follow-up times	≤10 (N = 53)	92.0 (32.5, 131.0)	0.782
	10–20 (N = 101)	98.0 (48.0, 133.5)
	>20 (N = 66)	90.0 (19.5, 137.0)
Co-trimoxazole^a	Yes (N = 156)	105.0 (62.5, 137.8)	0.000
Co-trimoxazole^a	No (N = 64)	60.5 (−68.3, 122.0)	0.000
Co-trimoxazole^b	Yes (N = 195)	93.0 (42.0, 133.0)	0.510
	No (N = 23)	96.0 (7.0, 164.0)
	Missing (N = 2)	—
HAART options^a	3TC + TDF + EFV (N = 153)	96.0 (55.5, 133.0)	0.035
	3TC + AZT + EFV (N = 30)	38.0 (−18.5, 130.0)
	NVP+3TC + AZT (N = 24)	73.5 (−37.3, 133.8)
	Others (N = 13)	114.0 (97.5, 152.0)
HAART options^b	3TC + TDF + EFV (N = 118)	91.5 (54.8, 136.3)	0.872
	3TC + AZT + EFV (N = 27)	92.0 (40.0, 122.0)
	NVP+3TC + AZT (N = 9)	93.0 (−26.5, 150.0)
	Others (N = 66)	95.0 (23.3, 133.0)
HAART replacement	Yes (N = 68)	83.5 (19.8, 131.8)	0.143
HAART replacement	No (N = 152)	97.0 (44.5, 136.8)	0.143
Cr^b	≤71.5 (N = 98)	83.0 (24.8, 128)	0.006
	>71.5 (N = 97)	113.0 (65.5, 155.0)
	Missing (N = 25)	86.0 (2.0, 114.0)
Liver function impairment^b	Yes (N = 73)	85.0 (34.0, 135.5)	0.310
	No (N = 124)	146.8 (100.5, 165.0)
	Missing (N = 23)	82.0 (−12.0, 113.0)
Leukopenia^b	Yes (N = 46)	90.0 (43.3, 123.8)	0.458
	No (N = 150)	98.5 (47.8, 150.3)
	Missing (N = 24)	80.5 (−7.3, 111.8)
Anemia^b	Yes (N = 24)	102.0 (38.0, 135.8)	0.920
	No (N = 172)	96.0 (45.0, 146.0)
	Missing (N = 24)	80.5 (−7.3, 128.5)

^aInfluencers in baseline, ^bInfluencers in follow-up. Data are presented Median (IQR). values were determined by the Mann–Whitney U test or Kruskal−Wallis test.